Vor Biopharma (VOR) Assets Average (2021 - 2026)

Vor Biopharma (VOR) has 6 years of Assets Average data on file, last reported at $485.4 million in Q1 2026.

• On a quarterly basis, Assets Average rose 284.96% year-over-year to $485.4 million in Q1 2026; TTM through Mar 2026 was $485.4 million, a 284.96% increase from a year earlier, with the FY2025 full-year figure at $303.5 million, up 78.0% from the prior year.
• Assets Average for Q1 2026 stood at $485.4 million, up from $320.2 million in the prior quarter.
• Over the last five years, Assets Average for VOR reached as high as $485.4 million in Q1 2026 and fell as low as $126.1 million in Q1 2025.
• Historically, Assets Average has averaged $224.2 million across 5 years, with a median of $215.5 million in 2022.
• Across the five-year window, Assets Average sank 45.66% in 2024 and jumped 284.96% in 2026, its largest moves.
• Year by year, Assets Average stood at $252.9 million in 2022, then declined by 16.73% to $210.6 million in 2023, then tumbled by 38.53% to $129.4 million in 2024, then soared by 147.36% to $320.2 million in 2025, then soared by 51.61% to $485.4 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $485.4 million in Q1 2026, $320.2 million in Q4 2025, and $190.8 million in Q3 2025.